Quarterly results round-up: Carl Zeiss Meditec beats forecasts, while Nobel Biocare downgrades guidance
This article was originally published in Clinica
Carl Zeiss Meditec, the medical technology arm of German optical group Carl Zeiss, has posted 13% revenue growth for the nine months ending 30 June. It recorded sales of €555m ($792.3m), driven by its microsurgery segment, where revenues were up 21% over the same period last year, at €194m. Revenues from its ophthalmic systems and surgical ophthalmology units both increased 8%, to €231.6m and €65.0m, respectively.